Castle Biosciences Reports 21% Revenue Increase in Q1 2025

Castle Biosciences ( (CSTL) ) just unveiled an update.

On May 5, 2025, Castle Biosciences reported a 21% increase in Q1 2025 revenue to $88 million compared to the same period in 2024, driven by a 33% rise in test reports for core products. The company raised its full-year revenue guidance to $287-297 million, reflecting strong growth and successful execution in its test portfolio. A significant milestone was achieved with over 200,000 orders for DecisionDx-Melanoma, which has been shown to improve patient survival rates. The company also announced the discontinuation of the IDgenetix test offering, effective May 2025, impacting its financials with a net loss of $25.8 million for the quarter.

Spark’s Take on CSTL Stock

According to Spark, TipRanks’ AI Analyst, CSTL is a Outperform.

Castle Biosciences is well-positioned financially with strong revenue growth and profitability improvements. However, technical analysis presents mixed signals, and the high P/E ratio suggests potential overvaluation. The potential Medicare coverage loss poses a risk, though the company shows resilience and growth potential. These factors collectively give the stock a moderate score.

To see Spark’s full report on CSTL stock, click here.

More about Castle Biosciences

Castle Biosciences is a company in the healthcare industry focused on improving health through innovative diagnostic tests that guide patient care. Their primary products include DecisionDx®-Melanoma, DecisionDx®-SCC, and TissueCypher®, with a market focus on dermatology and oncology.

YTD Price Performance: -30.99%

Average Trading Volume: 435,285

Technical Sentiment Signal: Buy

Current Market Cap: $558.1M

See more insights into CSTL stock on TipRanks’ Stock Analysis page.